For years, health care leaders have agreed on the promise of value-based care.
Align incentives. Improve outcomes. Reduce unnecessary utilization. Create a better experience for patients and providers.
But in the U.S. commercial health care market, agreement on the promise has not always produced agreement on the proof. Health plans, employers, and provider organizations can look at the same contract and reach different conclusions about whether it worked. One sees a downward trend in medical costs. Another sees higher shared-savings payments. A third sees quality improvement, but no clear financial return.
The uncomfortable truth is this:
Value-based care does not have an ROI problem. It has a value-measurement problem.
Contracts may change payment, but analytics determine whether organizations can see what changed, why it changed, and whether the improvement can be repeated. As commercial medical costs continue to rise, leading organizations are moving beyond retrospective scorecards and building a more complete view of value, one that connects financial performance, clinical outcomes, utilization, experience and equity.
ROI is more than shared savings
The most common ROI calculation is deceptively simple: compare actual spending with a benchmark, subtract program and incentive costs and divide the net benefit by the investment. That equation matters, but it is not enough.
A credible commercial value-based analytics model must answer harder questions. Was the population attributed consistently? Were changes in age, risk, benefit design, network, and unit prices accounted for? Did spending fall because care improved, or because services were deferred? Were savings concentrated in a small number of high-cost cases? Did the organization improve preventive care, chronic condition control, avoidable admissions, readmissions, and patient experience simultaneously?
This is why leading organizations measure value across a balanced set of outcomes:
- Risk-adjusted total cost of care and trend.
- Utilization, such as emergency department visits, inpatient admissions, and site-of-care shifts.
- Quality and clinical outcomes.
- Member experience and access.
- Provider engagement.
- The cost of operating the model itself.
ROI becomes meaningful only when the financial result can be traced to a clinical or operational change.
Real-world results show what good measurement looks like
Blue Cross Blue Shield of Massachusetts provides one of the best-known commercial examples. Its Alternative Quality Contract combines a global budget with substantial quality incentives. An eight-year study conducted by Harvard Medical School found average claims savings of $461 per member per year, 11.7% relative to a comparison group, with quality gains as well. The important lesson was not simply that spending slowed. The model used longitudinal claims, comparison populations, quality measures, and multi-year trend analysis to distinguish durable performance from a one-year variance.
In North Carolina, Blue Cross NC reported that its Blue Premier value-based program generated $157 million in savings in 2023 and $801 million cumulatively since 2019. The program served 1.4 million members and paid providers $132 million in incentives to improve quality and reduce costs. That result highlights another essential dimension of ROI: value must be sustainable for the provider organizations doing the work. Gross savings without accounting for incentive payments, care-management investments, and provider economics is not a complete business case.
As commercial medical costs continue to rise, leading organizations are moving beyond retrospective scorecards and building a more complete view of value, one that connects financial performance, clinical outcomes, utilization, experience and equity.
Self-insured employers are also measuring value at the episode level. A peer-reviewed RAND-led evaluation of a bundled Centers of Excellence program examined 2,372 surgeries across eight employers. For procedures completed through the program, employers saved an average of $16,144 per surgery (45% reduction) and total spending across the covered surgical categories fell 10.7%. The analysis also found that 30% of candidates were directed to nonsurgical care. Here, analytics revealed that value came not only from a lower bundle price, but also from appropriateness, avoided procedures, and better care pathways.
These examples are not directly interchangeable. They use different populations, benchmarks, time periods, and payment models. That is precisely the point: ROI should be evaluated against the design and intended outcomes of each program, not reduced to a universal savings percentage.
The next frontier is explainable value
Traditional reporting tells leaders whether a contract met its target. Value-based analytics should tell them what to do next.
The next generation of analytics connects claims, clinical data, pharmacy data, laboratory results, social risk indicators, provider performance and member engagement. This will help:
- Identify which populations and interventions are driving the result.
- Separate price, utilization and mix.
- Show whether avoidable emergency visits fell because primary care access improved, whether costs changed because medication adherence increased, or whether a surgical bundle succeeded because complications and post-acute utilization declined.
This level of explainability matters operationally. A payer can refine contract terms. A provider can target care-management resources. An employer can decide which benefit to expand. And all parties can work from a shared version of performance rather than negotiating over competing spreadsheets months after the performance year ends.
Measuring value continuously is a successful formula
Value-based care was never meant to be a different way of calculating payment after care was delivered. It was supposed to create a different way to deliver care.
That requires analytics that operate throughout the performance cycle: establishing a transparent baseline, monitoring leading indicators, identifying emerging risk, testing interventions, forecasting year-end performance, and validating outcomes. It also requires governance, shared definitions, agreed attribution rules, auditable benchmarks and timely data so that results are trusted by finance, clinical, actuarial, network and employer stakeholders.
The leading organizations will not define success by the size of a shared-savings check alone. They will know which interventions improved outcomes, which changes reduced avoidable costs, which providers and populations benefited and where inequities or unintended consequences remain.
Because the real ROI of value-based care is not simply spending less. It’s about building analytical intelligence to produce better outcomes, prove its value and do it again at scale.
